NO943341L - Sammensetninger for orale preparater - Google Patents

Sammensetninger for orale preparater

Info

Publication number
NO943341L
NO943341L NO943341A NO943341A NO943341L NO 943341 L NO943341 L NO 943341L NO 943341 A NO943341 A NO 943341A NO 943341 A NO943341 A NO 943341A NO 943341 L NO943341 L NO 943341L
Authority
NO
Norway
Prior art keywords
pct
composition
date sep
oral preparations
sec
Prior art date
Application number
NO943341A
Other languages
English (en)
Other versions
NO308022B1 (no
NO943341D0 (no
Inventor
Toshio Yajima
Nobuo Umeki
Hidefumi Hayashi
Ikuo Koyama
Ishii Kuniaki
Shigeru Itai
Kimihide Shimano
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NO943341L publication Critical patent/NO943341L/no
Publication of NO943341D0 publication Critical patent/NO943341D0/no
Publication of NO308022B1 publication Critical patent/NO308022B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
NO943341A 1992-03-12 1994-09-09 Sammensetninger for orale preparater NO308022B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5344292 1992-03-12
JP21990492 1992-08-19
PCT/JP1993/000291 WO1993017667A1 (en) 1992-03-12 1993-03-10 Composition for oral preparations

Publications (3)

Publication Number Publication Date
NO943341L true NO943341L (no) 1994-09-09
NO943341D0 NO943341D0 (no) 1994-09-09
NO308022B1 NO308022B1 (no) 2000-07-10

Family

ID=26394153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943341A NO308022B1 (no) 1992-03-12 1994-09-09 Sammensetninger for orale preparater

Country Status (12)

Country Link
US (1) US5707646A (no)
EP (1) EP0630233B1 (no)
JP (1) JP3265680B2 (no)
AT (1) ATE143258T1 (no)
AU (1) AU670428B2 (no)
CA (1) CA2131547C (no)
DE (1) DE69305069T2 (no)
ES (1) ES2095043T3 (no)
FI (1) FI109657B (no)
MX (1) MXPA93001352A (no)
NO (1) NO308022B1 (no)
WO (1) WO1993017667A1 (no)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2949448B2 (ja) * 1992-11-30 1999-09-13 ケーヴィ ファーマセチカル カンパニー 味を隠された医薬材料
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
CA2182282C (en) * 1994-02-16 2006-04-18 Jacqueline E. Briskin Process for preparing fine particle pharmaceutical formulations
US5728403A (en) * 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE29502547U1 (de) * 1995-02-16 1995-03-30 Röhm GmbH, 64293 Darmstadt Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
ATE352289T1 (de) * 1995-05-02 2007-02-15 Taisho Pharmaceutical Co Ltd Mittel zur oralen verabreichung
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
DE19617487A1 (de) † 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
DE19706979A1 (de) * 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
JP3466921B2 (ja) * 1998-06-03 2003-11-17 大塚製薬株式会社 味マスキング医薬製剤
WO2000018372A1 (fr) * 1998-09-30 2000-04-06 Taisho Pharmaceutical Co., Ltd. Granules pour preparations orales
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
EP2275141A1 (en) * 1999-03-17 2011-01-19 Daiichi Pharmaceutical Co., Ltd. Tastemasked pharmaceutical compositions
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini
IN191239B (no) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
NZ521368A (en) * 2000-03-28 2004-05-28 Biochemie Ges M Granulated particles of an active compound, with a film-forming coating resulting in the masked taste of said active compound
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
WO2001080826A2 (en) 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Taste masking coating composition
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
WO2001091761A1 (fr) * 2000-06-01 2001-12-06 Taisho Pharmaceutical Co.,Ltd. Matrices pour preparations orales
AU7105501A (en) 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
AU2001290239A1 (en) * 2000-09-19 2002-04-02 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
EP1333807A4 (en) * 2000-10-13 2005-06-29 Advancis Pharmaceuticals ERYTHROMYCIN DERIVATIVES WITH PROLONGED RELEASE
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
JP6154758B2 (ja) * 2000-11-21 2017-06-28 杏林製薬株式会社 ドライシロップ剤
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
PT1411899E (pt) * 2001-08-01 2009-04-24 Novartis Ag Composição de mascaramento de sabor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
PT1530457E (pt) 2002-08-12 2009-11-06 Bend Res Inc Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20080293801A1 (en) * 2003-11-14 2008-11-27 Pfizer Inc. Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005056542A1 (en) * 2003-12-09 2005-06-23 Pfizer Inc. Compositions comprising an hiv protease inhibitor
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
US8420115B2 (en) 2004-06-03 2013-04-16 Taisho Pharmaceutical Co., Ltd. Oral preparations and process for production thereof
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BRPI0814294A2 (pt) * 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
US20090163561A1 (en) * 2007-12-21 2009-06-25 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
BRPI0909469A2 (pt) * 2008-03-31 2015-12-29 Metabolex Inc compostos de oximetileno de arila e usos dos mesmos
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
DE102009019268A1 (de) * 2009-04-28 2010-11-11 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit poröser Matrix
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US8410127B2 (en) * 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
US9867809B2 (en) 2015-06-30 2018-01-16 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
MX2019010756A (es) 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
SG11202101503RA (en) 2018-08-31 2021-03-30 Pfizer Combinations for treatment of nash/nafld and related diseases
EP3956031A1 (en) 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
WO2020234726A1 (en) 2019-05-20 2020-11-26 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP3990452A1 (en) 2019-06-28 2022-05-04 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2021182467A1 (ja) * 2020-03-11 2021-09-16 沢井製薬株式会社 顆粒及びそれを用いた製剤
KR102838870B1 (ko) 2020-06-09 2025-07-24 화이자 인코포레이티드 멜라노코르틴 4 수용체 길항제로서의 스피로 화합물 및 그의 용도
JP7704982B2 (ja) 2021-12-01 2025-07-08 ファイザー・インク 糖尿病、腎疾患、ｎａｓｈおよび心不全を処置するための分枝鎖アルファケト酸デヒドロゲナーゼキナーゼ阻害剤としての３－フェニル－１－ベンゾチオフェン－２－カルボン酸誘導体
US20250129048A1 (en) 2021-12-06 2025-04-24 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
EP4598908A1 (en) 2022-10-07 2025-08-13 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
JP2025535295A (ja) 2022-10-18 2025-10-24 ファイザー・インク パタチン様ホスホリパーゼドメイン含有タンパク質３（ｐｎｐｌａ３）修飾因子
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
CN120731201A (zh) 2022-12-16 2025-09-30 辉瑞公司 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US3857939A (en) * 1971-08-18 1974-12-31 Hoffmann La Roche Chewable sodium-free vitamin c tablets
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5227171A (en) * 1989-04-18 1993-07-13 Taisho Pharmaceutical Co., Ltd. Process for producing flavored pharmaceutical preparation for oral administration using a cold water solution of polyvinyl acetal dimethylaminoacetate
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
JP2949448B2 (ja) * 1992-11-30 1999-09-13 ケーヴィ ファーマセチカル カンパニー 味を隠された医薬材料

Also Published As

Publication number Publication date
US5707646A (en) 1998-01-13
NO308022B1 (no) 2000-07-10
ES2095043T3 (es) 1997-02-01
MXPA93001352A (es) 2005-02-22
CA2131547A1 (en) 1993-09-16
JP3265680B2 (ja) 2002-03-11
AU3648493A (en) 1993-10-05
DE69305069T2 (de) 1997-03-13
FI944165L (fi) 1994-09-09
FI109657B (fi) 2002-09-30
ATE143258T1 (de) 1996-10-15
JPH06116138A (ja) 1994-04-26
EP0630233B1 (en) 1996-09-25
CA2131547C (en) 2002-02-12
NO943341D0 (no) 1994-09-09
DE69305069D1 (de) 1996-10-31
FI944165A0 (fi) 1994-09-09
WO1993017667A1 (en) 1993-09-16
AU670428B2 (en) 1996-07-18
EP0630233A1 (en) 1994-12-28

Similar Documents

Publication Publication Date Title
NO943341L (no) Sammensetninger for orale preparater
KR910011896A (ko) 신규한 글리코펩티드 유도체
DK0652773T3 (da) Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler
AU640137B2 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them
GR3035414T3 (en) Novel imidazole derivatives, their preparation and therapeutic applications.
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
BR9910928A (pt) Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina
MY101784A (en) Novel pharmacological compounds
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
KR880004808A (ko) 항신생 활성을 갖는 제약 조성물
ATE102604T1 (de) Diarylverbindungen als antiatherosklerotische mittel.
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
IT1264856B1 (it) Composizione farmaceutica ad attivita' analgesica
KR890014107A (ko) 백금 화학 요법약제
MX9203100A (es) Nuevos peptidos, su preparacion y su aplicacion.
DE69219901D1 (de) Adenosinderivate, Verfahren zu deren Herstellung und pharmazeutische Mittel
CA2107485A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR940006594A (ko) 후박 추출성분을 포함하는 치주질환 예방 치료제 조성물
KR900701262A (ko) 췌장염 등에 대한 치료제
KR900009675A (ko) 신규 백금 착화합물
AU3749195A (en) Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
IE780981L (en) 6-(substituted amino)-penam compounds
AU2096688A (en) Improvements in or relating to leukotriene antagonists

Legal Events

Date Code Title Description
MK1K Patent expired